ABSTRACT
T-DM1 (ado-trastuzumab emtansine; Kadcyla) is an antibody–drug conjugate (ADC) consisting of an anti-HER2 antibody linked to a microtubule inhibitor chemotherapy drugs, by combining the targeting ability of an antibody with a cytotoxic, ADCs can potentially deliver higher doses of chemotherapy into cancer cells whilst avoiding intolerable systemic toxicities. The KATHERINE study investigated whether the use of T-DM1 in the adjuvant setting improved oncological outcomes for women with early HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy (NACT).
